820 Heinz Ave
Berkeley, CA 94710
Ligandal is developing nonviral nanotechnology to replace the virus in gene therapy and enhance the delivery of genetic tools such as RNA, CRISPR, TALEN, and ZFN. Unlike existing techniques for introducing gene editing and RNA payloads into cells, Ligandal’s nanoparticles are capable of safely and effectively delivering a number of nucleic acids to specific cell types. The company is focusing on optimization of its nanotechnology in co-development partnerships with companies developing chimeric antigen receptors in T-cell (CAR-T) therapies and in academic collaborations for targeting and gene editing in bone marrow in the brain with researchers from Berkeley, Harvard and the Buck Institute.
Blood & Lymphatic Diseases, Cancer
Drug Delivery Technologies
Gene/Cell Therapy, Nanotechnology
Clinical Development Stage